Helix Presents Three-Year Genomic Screening Outcomes at ASHG Conference
Helix will present three-year genomic screening outcomes and new studies at the American Society of Human Genetics (ASHG) conference. The company's data resource now includes over 620,000 patient records.
San Mateo, Calif. – Precision medicine company Helix will present three-year outcomes from its genomic screening initiative at the opening plenary session of the American Society of Human Genetics (ASHG) conference. The company is also set to present new studies leveraging its GenoSphere™ resource.
The GenoSphere™ resource now comprises over 620,000 paired electronic health record (EHR), claims, and genomics data records. The new studies focus on areas including the effects of GLP-1 medications and genetic insights into dementia.
The data presented at ASHG aims to provide a deeper understanding of the long-term impact of genomic screening and its potential applications in disease prevention and treatment.
Helius GenoSphere™ serves as a comprehensive data foundation designed to advance precision medicine and improve patient care.